Latest FY capex
$729M
Revenue FY
$319M
Capex / Revenue
229%
Highest period
$954M
2026-06-30
Every capital-expenditure figure Core Scientific has reported to the SEC, unedited. Capex is the XBRL concept PaymentsToAcquirePropertyPlantAndEquipment; a capex/revenue ratio above 100% means the company is investing more than it earns to secure capacity. Each row links to the filing it came from.
BY FISCAL YEAR
| Fiscal year | Capex | YoY |
|---|---|---|
| FY2025 | $729M | +668% |
| FY2024 | $95M | +488% |
| FY2023 | $16M | -96% |
| FY2022 | $384M | — |
| FY2022 | $0M | — |
| FY2022 | $0M | — |
ALL REPORTED PERIODS (23)
| Period end | Period | Capex |
|---|---|---|
| 2026-06-30 | FY2026 Q2 | $954M |
| 2026-03-31 | FY2026 Q1 | $389M |
| 2025-12-31 | FY2025 FY | $729M |
| 2025-09-30 | FY2025 Q3 | $454M |
| 2025-06-30 | FY2025 Q2 | $210M |
| 2025-03-31 | FY2025 Q1 | $88M |
| 2024-12-31 | FY2024 FY | $95M |
| 2024-09-30 | FY2024 Q3 | $66M |
| 2024-06-30 | FY2024 Q2 | $35M |
| 2024-03-31 | FY2024 Q1 | $32M |
| 2023-12-31 | FY2023 FY | $16M |
| 2023-09-30 | FY2023 Q3 | $5M |
| 2023-06-30 | FY2023 Q2 | $2M |
| 2023-03-31 | FY2023 Q1 | $2M |
| 2022-12-31 | FY2022 FY | $384M |
| 2022-09-30 | FY2022 Q3 | $244M |
| 2022-06-30 | FY2022 Q2 | $239M |
| 2022-03-31 | FY2022 Q1 | $133M |
| 2021-12-31 | FY2022 FY | $0M |
| 2021-09-30 | FY2022 Q3 | $116M |
| 2021-06-30 | FY2022 Q2 | $39M |
| 2021-03-31 | FY2022 Q1 | $11M |
| 2020-12-31 | FY2022 FY | $0M |
Source: SEC XBRL company-concept API, concept PaymentsToAcquirePropertyPlantAndEquipment, CIK 1839341. See Methodology.